Having banked $38 million in a series A round late last year, cancer immunotherapy firm Potenza Therapeutics Inc. is "in good shape in terms of financing," thanks also to an undisclosed amount of new money from a deal with Astellas Pharma Inc., CEO Daniel Hicklin told BioWorld Today. Read More
DUBLIN – Has the era of truly personalized cancer immunotherapy begun? Biontech AG certainly thinks so – and the German biotech firm has published in vivo proof-of-concept data in the April 23, 2015, issue of Nature to back up its claims. Read More
With the consequences of the delayed response to the Ebola crisis still fresh on their minds, members of a House subcommittee Wednesday stressed the need to step up U.S. preparedness for bioterrorism attacks. Read More
Transitioning from discovery stage to human proof of concept is the next goal for cancer immunotherapy firm Jounce Therapeutics Inc., which added $56 million in series B funding to advance its pipeline and move into the clinic with a lead program directed against inducible T-cell co-stimulator, or ICOS. Read More
BOSTON – Shorter timelines to market and larger patient pools serve as major incentives for companies to bring clinical development work to China and India, although regulatory and cultural differences remain a hurdle. Read More
Markups on Amgen Inc.'s best-selling drugs, Enbrel (etanercept) and Neulasta (pegfilgrastim), and downsized R&D spending helped the company boost first quarter net income by 51 percent compared to a year ago. Read More
Baxter International Inc., of Deerfield, Ill., filed a complaint with the U.S. International Trade Commission alleging that Novo Nordisk A/S, of Bagsvaerd, Denmark, violated the Tariff Act in importing certain recombinant Factor VIII products into the U.S. Read More
Oberland Capital, of New York, an investment firm focused on the global health care industry, said it closed Oberland Capital Healthcare, an inaugural royalty and credit opportunities fund, with $425 million in capital commitments. Read More
Capricor Therapeutics Inc., of Los Angeles, said it was granted FDA orphan designation for its cell therapeutic candidate, CAP-1002, for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Read More
Pharmaleads SAS, of Paris, said the first patient has been included in a phase IIa study of oral PL37 in diabetic neuropathy. PL37, a dual enkephalinase inhibitor (DENKI), specifically targets the nociceptors located on peripheral nerve endings. Read More
Bayer HealthCare Pharmaceuticals Inc., of Whippany, N.J., said the FDA has accepted the filing of a supplemental biologics license application for Betaconnect (proposed name), another delivery option for Betaseron (interferon beta-1b), a treatment for relapsing-remitting multiple sclerosis. Read More
Curis Inc., of Lexington, Mass., presented data from in vitro and in vivo studies for CUDC-427, an antagonist of inhibitor of apoptosis (IAP) proteins. Read More
